These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 146566)

  • 1. Disposition of chlorozotocin in rats and dogs.
    Plowman J; Dingell JV; Adamson RH
    Cancer Treat Rep; 1978 Jan; 62(1):31-44. PubMed ID: 146566
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacologic disposition of chlorozotocin in mice.
    Mhatre RM; Green D; Panasci LC; Woolley PV; Schein PS
    Cancer Treat Rep; 1978 Aug; 62(8):1145-51. PubMed ID: 150943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of chlorozotocin: attempted amelioration of myelotoxicity by glucose administration.
    Panasci L; Comis R; Ginsberg S; Kohn L; Fitzpatrick A; Rubert M; Scalzo T
    Cancer Treat Rep; 1981; 65(7-8):647-50. PubMed ID: 6454483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of 14C and 3H-streptozotocin in dogs and toadfish.
    Ryo UY; Beierwaltes WH; Feehan P; Ice RD
    J Nucl Med; 1974 Jul; 15(7):572-6. PubMed ID: 4275999
    [No Abstract]   [Full Text] [Related]  

  • 5. Chlorozotocin. Mechanism of reduced bone marrow toxicity in mice.
    Panasci LC; Green D; Schein PS
    J Clin Invest; 1979 Oct; 64(4):1103-11. PubMed ID: 158033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular and molecular mechanisms of the bone marrow sparing effects of the glucose chloroethylnitrosourea chlorozotocin.
    Byrne P; Tew K; Jemionek J; MacVittie T; Erickson L; Schein P
    Blood; 1984 Apr; 63(4):759-67. PubMed ID: 6322885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.
    Kobayashi S; Sakai T; Dalrymple PD; Wood SG; Chasseaud LF
    Arzneimittelforschung; 1993 Dec; 43(12):1367-77. PubMed ID: 8141830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution and excretion of (3H)vincristine in the rat and the dog.
    Castle MC; Margileth DA; Oliverio VT
    Cancer Res; 1976 Oct; 36(10):3684-9. PubMed ID: 953993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
    Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
    Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
    Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
    Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of tissue disposition data from rats and dogs to determine species differences in input parameters for a physiological model for perchloroethylene.
    Dallas CE; Chen XM; Muralidhara S; Varkonyi P; Tackett RL; Bruckner JV
    Environ Res; 1994 Oct; 67(1):54-67. PubMed ID: 7925194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition of the opioid antagonist, LY255582, in rats and dogs.
    Swanson SP; Catlow J; Pohland RC; Chay SH; Johnson T
    Drug Metab Dispos; 1995 Sep; 23(9):916-21. PubMed ID: 8565781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metabolic disposition of (S)-2-(3-tert-butylamino-2-hydroxypropoxy)-3-cyanopyridine in rats, dogs, and humans.
    Vickers S; Duncan CA; Arison BH; Davies RO; Ferguson R; Zacchei AG
    Drug Metab Dispos; 1980; 8(3):163-7. PubMed ID: 6104580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-Chlorozotocin.
    Johnston TP; McCaleb GS; Anderson T; Murinson DS
    J Med Chem; 1979 May; 22(5):597-9. PubMed ID: 156793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition and tissue levels of [3H]vindesine in rats.
    Culp HW; Daniels WD; McMahon RE
    Cancer Res; 1977 Sep; 37(9):3053-6. PubMed ID: 884663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption, distribution and excretion of eprazinone in animals.
    Constantin M; Pognat JF; Streichenberger G
    Arzneimittelforschung; 1974 Nov; 24(11):1793-8. PubMed ID: 4480052
    [No Abstract]   [Full Text] [Related]  

  • 17. Studies on the absorption, distribution and excretion of propranolol in rat, dog and monkey.
    Hayes A; Cooper RG
    J Pharmacol Exp Ther; 1971 Feb; 176(2):302-11. PubMed ID: 4998689
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II evaluation of chlorozotocin in patients with renal cell carcinoma.
    Gralla RJ; Yagoda A
    Cancer Treat Rep; 1979 Jun; 63(6):1007-8. PubMed ID: 157222
    [No Abstract]   [Full Text] [Related]  

  • 19. Disposition and metabolism of 3H-cyclazocine in dogs.
    Mulé SJ; Gorodetzky CW; Clements TH
    Adv Biochem Psychopharmacol; 1973; 8(0):503-23. PubMed ID: 4794906
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II evaluation of chlorozotocin in advanced bronchogenic carcinoma.
    Creagan ET; Eagan RT; Fleming TR; Frytak S; Kvols LK; Ingle JN
    Cancer Treat Rep; 1979; 63(11-12):2105-6. PubMed ID: 230898
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.